MX337722B - Uso de nuevos inhibidores de pan-cdk para tratar tumores. - Google Patents

Uso de nuevos inhibidores de pan-cdk para tratar tumores.

Info

Publication number
MX337722B
MX337722B MX2012011427A MX2012011427A MX337722B MX 337722 B MX337722 B MX 337722B MX 2012011427 A MX2012011427 A MX 2012011427A MX 2012011427 A MX2012011427 A MX 2012011427A MX 337722 B MX337722 B MX 337722B
Authority
MX
Mexico
Prior art keywords
treating tumors
cdk inhibitors
novel pan
pan
novel
Prior art date
Application number
MX2012011427A
Other languages
English (en)
Other versions
MX2012011427A (es
Inventor
Gerhard Siemeister
Ulrich Lücking
Antje Margret Wengner
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MX2012011427A publication Critical patent/MX2012011427A/es
Publication of MX337722B publication Critical patent/MX337722B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere al uso de derivados seleccionados de anilinopirimidina sustituidos con sulfoximina de la fórmula (I) para tratar tumores (Ver Formula).
MX2012011427A 2010-04-01 2011-03-28 Uso de nuevos inhibidores de pan-cdk para tratar tumores. MX337722B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010014426A DE102010014426A1 (de) 2010-04-01 2010-04-01 Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
PCT/EP2011/054733 WO2011120922A1 (de) 2010-04-01 2011-03-28 Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren

Publications (2)

Publication Number Publication Date
MX2012011427A MX2012011427A (es) 2013-03-05
MX337722B true MX337722B (es) 2016-03-16

Family

ID=43858236

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011427A MX337722B (es) 2010-04-01 2011-03-28 Uso de nuevos inhibidores de pan-cdk para tratar tumores.

Country Status (20)

Country Link
US (1) US20130210846A1 (es)
EP (1) EP2552450A1 (es)
JP (1) JP5816259B2 (es)
KR (1) KR20130014678A (es)
CN (1) CN102834100A (es)
AU (1) AU2011234654B2 (es)
BR (1) BR112012024422A2 (es)
CA (1) CA2794996A1 (es)
CL (1) CL2012002753A1 (es)
CR (1) CR20120502A (es)
DE (1) DE102010014426A1 (es)
DO (1) DOP2012000260A (es)
EC (1) ECSP12012198A (es)
MA (1) MA34098B1 (es)
MX (1) MX337722B (es)
NZ (1) NZ602710A (es)
SG (2) SG183925A1 (es)
TN (1) TN2012000469A1 (es)
UA (1) UA108494C2 (es)
WO (1) WO2011120922A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201491732A1 (ru) * 2012-03-21 2015-08-31 Байер Интеллектуэль Проперти Гмбх Применение (rs)-s-циклопропил-s-(4-{[4-{[(1r,2r)-2-гидрокси-1-метилпропил]окси}-5-(трифторметил)пиримидин-2-ил]амино}фенил)сульфоксимида для лечения специфических опухолей
BR112015021550A2 (pt) * 2013-03-07 2017-07-18 Bayer Pharma AG uso de (rs)-s-ciclopropil-s-(4-{[4-{[(1r, 2r)-2-hidróxi-1-metilpropil]oxi}-5-(trifluorometil)pirimidin-2-il]amino}fenil)sulfóximida para tratamento de tumores específicos
PL2968294T3 (pl) * 2013-03-13 2019-10-31 Oncoceutics Inc 7-Benzylo-10-(2-metylobenzylo)-2,6,7,8,9,10-heksahydroimidazo[1,2-a]pirydo[4,3-d]pirymidyn-5(3H)-on do zastosowania w leczeniu nowotworu
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
JP2016526540A (ja) * 2013-06-21 2016-09-05 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンジルピラゾール
WO2015071231A1 (de) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
AU744986B2 (en) 1997-07-12 2002-03-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
JP4291135B2 (ja) 2001-05-29 2009-07-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｃｄｋ阻害性ピリミジン、それらの製造および薬剤としての使用
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2179991A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
TN2012000469A1 (en) 2014-01-30
CL2012002753A1 (es) 2013-01-18
EP2552450A1 (de) 2013-02-06
UA108494C2 (uk) 2015-05-12
CR20120502A (es) 2012-11-20
SG183925A1 (en) 2012-10-30
ECSP12012198A (es) 2012-10-30
WO2011120922A1 (de) 2011-10-06
AU2011234654A1 (en) 2012-10-25
CA2794996A1 (en) 2011-10-06
BR112012024422A2 (pt) 2016-05-31
AU2011234654B2 (en) 2015-08-06
NZ602710A (en) 2014-05-30
DE102010014426A1 (de) 2011-10-06
MX2012011427A (es) 2013-03-05
DOP2012000260A (es) 2013-03-31
SG10201502566SA (en) 2015-05-28
MA34098B1 (fr) 2013-03-05
US20130210846A1 (en) 2013-08-15
KR20130014678A (ko) 2013-02-08
JP5816259B2 (ja) 2015-11-18
JP2013523680A (ja) 2013-06-17
CN102834100A (zh) 2012-12-19

Similar Documents

Publication Publication Date Title
PH12017502141A1 (en) Compounds and their methods of use
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MY162933A (en) Chemical compounds
CR20130045A (es) Compuestos terapéuticos
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
AU2012213775A8 (en) 7-azaindole derivatives
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
CR20120637A (es) Triazolopiridinas sustituidas
MX349548B (es) Compuestos de tienopirimidina.
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
MY159995A (en) Pyrimidinyl indole compounds
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
GB201016442D0 (en) Novel acridine derivatives
PH12014501794A1 (en) New pediatric uses of cabazitaxel
TN2014000342A1 (en) New pediatric uses of cabazitaxel
UA38583U (ru) 3-МЕТИЛ-7-n-ХЛОРБЕНЗИЛИДЕНГИДРАЗИНОКСАНТИН, КОТОРЫЙ ПРОЯВЛЯЕТ АНТИОКСИДАНТНОЕ ДЕЙСТВИЕ
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration